exibility for both organic and 
inorganic growth. IBA reiterates its previously announced mid-term 
guidance, based on the assumption that macro-
economic factors normalize over the coming 
years: supply chain issues stabilize, inflation 
drops towards 3%, and challenges accessing 
certain regions reduce. In addition, guidance is 
on the basis that order intake remains solid, especially in the Proton Therapy and Industrial 
Solutions businesses.